DiscoverThe Uromigos
The Uromigos
Claim Ownership

The Uromigos

Author: The Uromigos

Subscribed: 65Played: 6,271
Share

Description

Broadcasting the latest developments in GU cancer

Hosted by Brian Rini and Tom Powles

Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center
Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London
506 Episodes
Reverse
The final session of this year’s meeting discusses exciting T cell engager and CAR-T data from ESMO 2026. Are these approaches finally ready for prime time in mRCC? 
Doublet therapy has produced positive results in the adjuvant and refractory RCC settings. Are they the standard of care and what is the role of monotherapy for individual patients?
Recent attempts to build on the IO-doublet backbone in front-line clear cell RCC therapy have failed including LITESPARK-012. The panel discusses issues that have impacted these trials and where we go from here.
Several third agents added to the ADT/ARPI backbone in mHSPC have emerged in the last year including radioligands and PARP inhibitors. Navigating application to individual patients is discussed by our expert panel.
Several phase 3 trials in high-risk localized prostate cancer have reported this year including PROTEUS and DASL. The panel debates if and how these will impact treatment of this patient population.
loading
Comments